Journal
RADIOTHERAPY AND ONCOLOGY
Volume 93, Issue 3, Pages 639-644Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.radonc.2009.09.006
Keywords
EGFR; Lapatinib; CI-1040; MEK/ERK; Resistance; Breast cancer
Funding
- NCI NIH HHS [CA83753, R01 CA115888-04, R01 CA115888, CA115888, K08 CA083753] Funding Source: Medline
Ask authors/readers for more resources
Background and purpose, We recently showed that lapatinib, an EGFR/HER2 inhibitor, radiosensitized breast cancer cells of the basal and HER2+ subtypes. The purpose of this study was to Identify the downstream signaling pathways responsible for lapatinib-mediated radiosensitizatton in breast cancer. Materials and methods Response of EGFR downstream signaling pathways was assessed by Western blot and clonogenic cell survival assays in breast tumor cells after irradiation (5 Gy), lapatinib. CI-1040, of combined treatment. Results: In SUM102 cells. an EGFR+ basal breast cancer cell line, exposure to Ionizing radiation elicited strong activation of ERK1/2 and JNK, which was blocked by lapatinib, and weak/no activation of p38. AKT or STAT3. Direct inhibition of MEK1 with CI-1040 resulted in 95% Inhibition of surviving colonies when combined with radiation while inhibition of JNK with 511600125 had no effect. Lapatinib-mediated radiosensitization of SUM 102 cells was completely abrogated with expression of constitutively active Raf Treatment of lapatinib-resistant SUM185 cells with CI-1040 restored radiosensitization with 45% fewer surviving colonies when combined with radiation. Conclusions. These data suggest that radiosensitization by lapatimb is mediated largely through inhibition of MEK/ERK and that direct inhibition of this pathway may provide an additional avenue of radiosensitizatton in EGFR+ or HER2+ breast cancers (C) 2009 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 93 (2009) 639-644
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available